Antiviral nucleoside derivatives

Details Antiviral nucleoside derivatives Antiviral nucleoside derivatives

2005-01-25

2005-01-25

Wilson, James O. (Department: 1623)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C514S934000, C514S894000, C536S028510, C536S028500, C536S055300

Reexamination Certificate

active

06846810

ABSTRACT:
The present invention relates to nucleoside derivatives for the treatment of Hepatitis C viral infections including compounds of formula I, pharmaceutical compositions comprising these compounds and methods for treatment or prophylaxis of Hepatitis C Virus mediated diseases employing said compounds in monotherapy or in combination therapy. The present invention further provides a process for preparing 1′,3′,4′-triacyl pyrimidine nucleoside from a N, 1′,3′,4′-tetraacylpyrimidine nucleoside

REFERENCES:
patent: 3998807 (1976-12-01), Moffatt
patent: 4957924 (1990-09-01), Beauchamp
patent: 5216142 (1993-06-01), Horrobin et al.
patent: 5449664 (1995-09-01), Verheyden et al.
patent: 6184376 (2001-02-01), Leanna et al.
patent: 0 343 133 (1989-11-01), None
patent: 0 375 329 (1990-06-01), None
patent: WO 9307163 (1993-04-01), None
patent: WO 9422887 (1994-10-01), None
patent: WO 9424134 (1994-10-01), None
patent: WO 0023454 (2000-04-01), None
patent: WO 0145509 (2001-06-01), None
patent: WO 0168034 (2001-09-01), None
patent: WO 0190121 (2001-11-01), None
patent: WO 02100415 (2002-12-01), None
Balimane, et al., “Direct Evidence for Peptide Transporter (PEPT1)-Mediated Uptake of a Nonpeptide Prodruc, Valacyclovir,” Biochemical and Biophysical Research Communications, (1998) pp. 246-251, vol. 250, Article No. RC989298.
Beauchamp, et al., “Amino Acid Ester Prodrugs of Acyclovir,” Antiviral Chemistry & Chemotherapy, (1992), pp. 157-164, 3(3).
Chamberlain, et al., “2'-Ester Prodrugs of the Varicella-Zoster Antiviral Agent, 6-Methoxypurine Arabinoside,” Antiviral Chemistry & Chemotherapy, (1992), pp. 371-378, 3(6).
Harnden, et al., “Prodrugs of the Selective Antiherpesvirus Agent 9-[4-Hydroxy-3-(hydroxymethyl)but-1-yl]guanine (BRL 39123) with Improved Gastrointestinal Absorption Properties,” J. Med. Chem., (1989), pp. 1738-1743, 32.
Hodge, et al., “Selection of an Oral Prodrug (BRL 42810; Famciclovir) for the Antiherpesvirus Agent BRL 39123 [9-4(-Hydroxy-3-Hydroxymethylbut-1-yl)Guanine; Penciclovir],” Antimicrobial Agents and Chemotherapy, (1989), pp. 1765-1773, 33(10).
Jones, et al. “Di- and Triester Prodrugs of the Varicella-Zoster Antiviral Agent 6-Methoxypurine Arabinoside,” J. Med. Chem, (1992), pp. 56-63, 35.
Kim, et al., “Synthesis and Evaluation of 2-Amino-9-(1,3-dihydroxy-2-propoxymethyl)-6-fluoropurine Mono- and Diesters as Potential Prodrugs of Ganciclovir,” J. Med. Chem., (1999), pp. 324-328, 42.
Maag, Hans et al., “Synthesis and Anti-HIV Activity of 4'-Azido- and 4'-Methoxynucleosides,”J. Med. Chem., (1992), pp. 1440-1451, 35.
Moffatt, J.G., “Chemical Transformations of the Sugar Moiety of Nucleosides”, Nucleoside Analogues, (R. T. Walker, E. De Clercq, & F. Eckstein, eds.), (1979), pp. 71-164, Plenum Press, New York. (see p. 144).
Nielsen, et al., “Human Peptide Transporters: Therapeutic Applications,” Expert Opinion, Ther. Patents (2002), pp. 1329-1350, 12(9), Ashley Publications.
Pue, et al., “Pharmacokinetics of Famciclovir in Man,” Antiviral Chemistry & Chemotherapy, (1993), pp. 47-55, 4, Suppl. 1.
Rubio-Aliaga, et al., “Mammalian Peptide Transporters as Targets for Drug Delivery,” Trends in Pharmacological Sciences, (2002), pp. 434-440, 23(9).

Affiliated with

Also associated with

Rating

Antiviral nucleoside derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antiviral nucleoside derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antiviral nucleoside derivatives will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3422105